Literature DB >> 21495837

Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD.

Robert M Reed1, Aldo Iacono, Andrew DeFilippis, Steven Jones, Michael Eberlein, Noah Lechtzin, Reda E Girgis.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) in COPD carries a poor prognosis. Statin therapy has been associated with numerous beneficial clinical effects in COPD, including a possible improvement in PH. We examined the association between statin use and pulmonary hemodynamics in a well-characterized cohort of patients undergoing evaluation for lung transplantation.
METHODS: We conducted a cross-sectional analysis of 112 subjects evaluated for lung transplant with a diagnosis of COPD. Clinical characteristics, pulmonary function, cardiac catheterization findings and medical comorbidities were compared between statins users and non-users.
RESULTS: Thirty-four (30%) subjects were receiving statin therapy. Statin users were older and had an increased prevalence of systemic hypertension and coronary artery disease (CAD). Mean pulmonary arterial pressure (mPAP) in the statin group was lower [26 ± 7 vs 29 ± 7 mmHg, p = 0.02], as was pulmonary artery wedge pressure (PAWP) [12 ± 5 vs. 15 ± 6 mmHg, p = 0.02]. Pulmonary vascular resistance did not differ between the groups. In multiple regression analysis, statin use was associated with a 4.2 mmHg (95% CI: 2 to 6.4, p = <0.001) lower PAWP and a 2.6 mmHg (95% CI: 0.3 to 4.9, p = 0.03) reduction in mPAP independent of PAWP.
CONCLUSIONS: In patients with severe COPD, statin use is associated with significantly lower PAWP and mPAP. These finding should be evaluated prospectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21495837     DOI: 10.3109/15412555.2011.558545

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  18 in total

1.  Simvastatin protects hepatocytes from apoptosis by suppressing the TNF-α/caspase-3 signaling pathway in mice with burn injury.

Authors:  Gaofeng Zhao; Yong-Ming Yu; Masao Kaneki; Ronald G Tompkins; Alan J Fischman
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

2.  Pulmonary arterial enlargement and acute exacerbations of COPD.

Authors:  J Michael Wells; George R Washko; MeiLan K Han; Naseer Abbas; Hrudaya Nath; A James Mamary; Elizabeth Regan; William C Bailey; Fernando J Martinez; Elizabeth Westfall; Terri H Beaty; Douglas Curran-Everett; Jeffrey L Curtis; John E Hokanson; David A Lynch; Barry J Make; James D Crapo; Edwin K Silverman; Russell P Bowler; Mark T Dransfield
Journal:  N Engl J Med       Date:  2012-09-03       Impact factor: 91.245

3.  Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases.

Authors:  Ming-Zhou Zhang; De-Hui Qian; Jian-Cheng Xu; Wei Yao; Ye Fan; Chang-Zheng Wang
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 4.  Right ventricular dysfunction in chronic lung disease.

Authors:  Todd M Kolb; Paul M Hassoun
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

5.  Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study.

Authors:  Luise Holzhauser; Ninel Hovnanians; Parham Eshtehardi; M Khalid Mojadidi; Yi Deng; David Goodman-Meza; Pavlos Msaouel; Yi-An Ko; Ronald Zolty
Journal:  Heart Vessels       Date:  2017-03-16       Impact factor: 2.037

Review 6.  The role of pulmonary arterial stiffness in COPD.

Authors:  Jonathan R Weir-McCall; Allan D Struthers; Brian J Lipworth; J Graeme Houston
Journal:  Respir Med       Date:  2015-06-12       Impact factor: 3.415

7.  Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Fangying Chen; Mei Yang; Chun Wan; Lin Liu; Lei Chen
Journal:  Ann Transl Med       Date:  2019-12

Review 8.  Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD.

Authors:  J Michael Wells; Mark T Dransfield
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-29

9.  Evaluation of the Effects of Atorvastatin on the Treatment of Secondary Pulmonary Hypertension due to Chronic Obstructive Pulmonary Diseases: A Randomized Controlled Trial.

Authors:  Seyed Ali Javad Moosavi; Hanieh Raji; Masoomeh Faghankhani; Rostam Yazdani; Mansour Esmaeili
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

10.  Impact of Statins on Gene Expression in Human Lung Tissues.

Authors:  Jérôme Lane; Stephan F van Eeden; Ma'en Obeidat; Don D Sin; Scott J Tebbutt; Wim Timens; Dirkje S Postma; Michel Laviolette; Peter D Paré; Yohan Bossé
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.